REQUEST A DEMO
Total
USD $0.00
Search more companies

Mabion S.A. (Poland)

Main Activities: Pharmaceutical Preparation Manufacturing | Research and Development in Biotechnology (except Nanobiotechnology) | Medical Laboratories
Full name: Mabion S.A. Profile Updated: November 19, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Mabion S.A. is a biotechnology company, researches and develops biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases in Poland. It develops MabionCD20, an oncology drug for the treatment of lymphomas and leukemia blood cancers, as well as rheumatoid arthritis. MabionHER2, an oncology drug for the treatment of breast cancer and MabionVEGF_Fab is a drug for the treatment of various diseases resulting in vision impairment in adults. The company also develops MabionEGFR, an oncology drug for the treatment of metastatic colorectal cancer and MabionVEGF, an oncology drug for the treatment of colon or rectal cancer, metastatic breast cancer, and metastatic or recurrent lung cancer with other anticancer drugs.

Headquarters
ul. Langiewicza 60
Konstantynow Lodzki; Lodzkie; Postal Code: 95-050

Contact Details: Purchase the Mabion S.A. report to view the information.

Website: http://www.mabion.eu

Basic Information
Total Employees:
Purchase the Mabion S.A. report to view the information.
Outstanding Shares:
Purchase the Mabion S.A. report to view the information.
Registered Capital:
Purchase the Mabion S.A. report to view the information.
Financial Auditors:
Purchase the Mabion S.A. report to view the information.
Incorporation Date:
October 29, 2009
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Purchase this report to view the information.
Management Board Member
Ownership Details
Purchase this report to view the information.
16.55%
Purchase this report to view the information.
10.63%
Purchase this report to view the information.
9.12%
Company Performance
Financial values in the chart are available after Mabion S.A. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
-38.88%
Total operating revenue
-38.73%
Operating profit (EBIT)
-80.54%
EBITDA
-70.17%
Net Profit (Loss) for the Period
-72.89%
Total assets
-13.88%
Total equity
9.8%
Operating Profit Margin (ROS)
-30.05%
Net Profit Margin
-22.53%
Return on Equity (ROE)
-27.22%
Debt to Equity Ratio
-27.53%
Quick Ratio
-0.25%
Cash Ratio
0.29%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?